News | January 20, 2022
Natco Pharma signs agreement with Medicines Patent Pool
This agreement allows Natco to expand access to Covid-19 medicines in 105 countries in generic name
This agreement allows Natco to expand access to Covid-19 medicines in 105 countries in generic name
The recommended daily dose for Ryaltris is 2 sprays in each nostril twice daily
The HALO AP platform was developed by Indica Labs to address the specific needs of anatomic pathology labs by supporting a wide range of tissue-based workflows, including primary diagnosis, secondary consults, tumour boards, clinical trials, synoptic reporting, quantitative analytics, and AI
Innovative market development collaboration also signed, expanding the availability of select Novartis oncology products in regions across China currently not covered by Novartis
The deepCDR engine combines deep sequencing and deep learning methods with a proprietary mammalian display process to select from a wide range of antibodies and rapidly identify candidates with the highest possible affinity and developability profiles
Orencia is the first FDA-approved therapy to prevent acute graft versus host disease following hematopoietic stem cell transplant
The platform’s technology works as a compression algorithm for molecular testing
The nutraceutical sector is on the cusp of exponential growth and Covid-19 has accelerated the pace of its applications. Dr R.B Smarta, CMD, Interlink, shares his perspective on the growth opportunities and challenges for the sector
New safety data show a consistent benefit-risk profile across all Ocrevus clinical trials
If approved, Gavreto will be the first and only targeted treatment approved by the EMA that includes first-line treatment of people with RET fusion-positive advanced NSCLC
Subscribe To Our Newsletter & Stay Updated
